Institut De Recherches Internationales Servier

This early-phase trial tested a new drug called S095029, alone and combined with another drug (Sym021), in 41 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety and see if the drugs could shrink tumors. The study com…

This early-phase study tested two experimental drugs, AG-120 and AG-881, in 49 adults with a recurrent, slow-growing brain tumor (low grade glioma) that has a specific IDH1 gene mutation. The goal was to see if these drugs could lower a substance called 2-HG in the tumor tissue b…

This study tested a new drug called S65487, which blocks a protein that helps cancer cells survive, combined with a standard drug azacitidine. The trial included 57 adults with untreated acute myeloid leukemia who were not healthy enough for intensive chemotherapy. The goal was t…

This early-phase study tested an oral drug called AG-120 in 174 people with advanced solid tumors (including bile duct cancer, cartilage cancer, and brain tumors) that have a specific IDH1 gene mutation. The goal was to find a safe dose and see if the drug could shrink or slow tu…

This study tested a new combination of four drugs (irinotecan liposome, oxaliplatin, 5-FU, and leucovorin) in 41 Japanese adults with advanced pancreatic cancer that had not been treated before. The goal was to see if the treatment could shrink tumors and to check its safety. Par…

This early-phase study tested an oral drug called AG-881 in 95 adults with advanced solid tumors, including brain tumors (gliomas), that have specific IDH gene mutations. The main goals were to check safety, find the best dose, and see how the drug works in the body. While not a …